非瓣膜性房颤老年患者华法林用药依从性及相关因素调查研究

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (566 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the compliance and related factors of Warfarin in elderly patients with non-valvular atrial fibrillation. Methods Ninety-six elderly patients with non-valvular atrial fibrillation admitted to Wuhan Asian Heart Hospital from March 2016 to December 2018 were selected as the research objects. The compliance of Warfarin in elderly patients with non-valvular atrial fibrillation was investigated and the related factor effecting the compliance of Warfarin in elderly patients with non-valvular atrial fibrillation was analyzed. Results A total of 96 questionnaires were sent out and 82 valid questionnaires were recovered. The effective recovery rate was 85.42%. Among them, 43.90% of the patients had good drug compliance. Good drug compliance of patients was related to gender, education level, number of complications, age and WRKS scores (all P ＜ 0.05). However, there were no related to marital status, occupation, drinking history, smoking history and the number of combined drugs (P ＞ 0.05). The influencing factors of drug compliance in elderly patients with non-valvular atrial fibrillation were male (OR = 1.661, 95%CI: 1.108, 1.924, P = 0.037), primary school education or below (OR = 2.512, 95%CI: 1.494，4.324, P = 0.009), number of complications≥3 types (OR = 1.573, 95%CI: 0.616, 1.234, P = 0.026) and WRKS scores≤8 points(OR = 1.798, 95%CI: 1.103， 3.506, P = 0.017). Conclusion Elderly patients with non-valvular atrial fibrillation have poor compliance with Warfarin. They are susceptible influenced by gender, education level, number of complicationsand WRKS scores. Clinical attention should be paid to the above factors as much as possible to improve the compliance of Warfarin in elderly patients with non-valvular atrial fibrillation.

Key words： Non-valvular atrial fibrillation Elderly Warfarin Compliance Related factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yahong XIAO Hongyan

Cite this article:

WANG Yahong XIAO Hongyan. Investigation on compliance and related factors of warfarin in elderly patients with non-valvular atrial fibrillation[J]. 中国医药导报, 2019, 16(33): 59-62.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I33/59

[1] Yu YB，Liu J，Fu GH，et al. Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation：Meta-analysis of random control trial [J]. Medicine （Baltimore），2018，97（46）：e12841.
[2] Worner F，Marzo C，Rivera K，et al. Prospective and Centralized Follow-Up of a Territorial Protocol of Use of Direct Oral Anticoagulants in Non Valvular Atrial Fibrillation [J]. Eur Cardiol，2017，12（2）：108.
[3] 雷志毅，刘国伟，何晓芳，等.血栓对非瓣膜型房颤患者左心耳及相邻结构形态学影响的MSCT研究[J].中国医学计算机成像杂志，2017，2（4）：325-328.
[4] 陈文文，党和勤，耿涛，等.非瓣膜性房颤患者华法林用药依从性及其影响因素的调查分析[J].中国药房，2017， 28（27）：3763-3767.
[5] 王颖，谭湘萍，严鹏科，等.房颤合并冠心病患者服用华法林致INR异常1例的药学监护[J].中国药师，2015，18（1）：105-108.
[6] 黄从新，张澍，黄德嘉，等.心房颤动：目前的认识和治疗建议-201[J].中国心脏起搏与心电生理杂志，2015，29（5）：377-434.
[7] Wang Y，Kong MC，Ko Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin [J]. Thromb Haemost，2012，108（4）：789-795.
[8] 方曙静，林征，孙国珍，等.非瓣膜病性心房颤动患者华法林抗凝知识调查分析[J].护理学杂志，2010，25（23）：37-39.
[9] Rivera K，Marzo C，Sans N，et al. Consensus is Possible: Initiation and Exchange of Oral Anticoagulants in Non-valvular Atrial Fibrillation，According to a Territorial Protocol in a Period of Time [J]. Eur Cardiol，2017，12（2）：104.
[10] 黄燕，向倩，周颖，等.临床科室华法林用药特点分析[J].中国临床药理学杂志，2015，31（24）：2454-2456.
[11] 卢奕，温连安，李东，等.非瓣膜性房颤达比加群酯抗凝治疗的疗效及安全性评价[J].中国药业，2017，26（6）：49-51.
[12] 吴惠珍，张翠改，李刚，等.住院患者华法林用药情况分析[J].中国医药，2012，7（6）：739-740.
[13] 钟竹青，段应龙，谢建飞，等.出院患者华法林用药安全知识与能力水平的调查及分析[J].中国护理管理，2016， 16（5）：681-684.
[14] 岳慧杰，宋小骏，谢学建，等.137例瓣膜置换术后住院患者华法林用药的影响因素[J].中国药师，2011，14（8）：1157-1158.
[15] 庄文芳，吴德沛，王兆钺，等.上海地区服用华法林人群相关基因型及非遗传因素对用药剂量的影响[J].中华血液学杂志，2014，35（1）：13-17.
[16] 黄琳，燕兰云，吴婷，等.不同年龄段非瓣膜性房颤患者防治脑梗死的用药情况比较[J].中国现代医学杂志，2015， 25（34）：23-26.
[17] 孙彬，孙琦，高宇，等.服用华法林患者住院期间用药的合理性分析[J].中国医药指南，2018，16（8）：9-10.
[18] 田霞，崔颖.某院121例脑卒中合并非瓣膜性房颤患者的用药现状分析[J].现代医院，2018，18（9）：1371-1373.
[19] 杨延宗，孙源君.新型抗凝药物循证证据进一步积累——欧洲心律学会关于非瓣膜病心房颤动患者应用新型抗凝药指南更新解读[J].中国循环杂志，2016， 31（z2）：134-138.
[20] 鲁秀秀.新型抗凝药达比加群与华法林用于老年非瓣膜性房颤患者抗凝治疗的有效性与安全性比较[D].济南：山东大学，2018.
[21] 杨丽莎.强化心理护理干预对心脏换瓣术后病人出院后服用华法林的依从性的影响[J].现代诊断与治疗，2017， 28（12）：2340-2342.